Proteomics in Alzheimer's disease: Insights into potential mechanisms of neurodegeneration

Journal of Neurochemistry

Volumn 86, Issue 6, 2003, Pages 1313-1327

  Butterfield, D Allan ^a   Boyd Kimball, Debra ^a   Castegna, Alessandra ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Alzheimer's disease; Mechanisms of neurodegeneration; Oxidative stress; Oxidatively modified proteins; Proteomics

Indexed keywords

2',3' CYCLIC NUCLEOTIDE 3' PHOSPHODIESTERASE; ALPHA CRYSTALLIN; CASPASE 3; CHAPERONE; CHOLINERGIC RECEPTOR; ENDOSULFAN; ENOLASE; GLIAL FIBRILLARY ACIDIC PROTEIN; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 70; PROTEASOME; PROTEIN; PROTEIN BCL 2; PROTEIN P21; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); STATHMIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; TRYPSIN; VOLTAGE GATED CHANNEL FORMING PROTEIN;

ALZHEIMER DISEASE; BIOCHEMISTRY; DATA BASE; HUMAN; MOLECULAR WEIGHT; NERVE DEGENERATION; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEOMICS; REVIEW; TWO DIMENSIONAL ELECTROPHORESIS;

ALZHEIMER DISEASE; ANIMALS; HUMANS; NEURONS; OXIDATIVE STRESS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEINS; PROTEOMICS;

RODENTIA;

EID: 0141767139     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2003.01948.x     Document Type: Review

References (89)

1. Aebersold R. and Goodlett D. R. (2001) Mass spectrometry in proteomics. Chem. Rev. 101, 269-295.
2. Aksenov M. Y., Tucker H. M., Nair P., Askenova M. V., Butterfield D. A., Estus S. and Markesbery W. R. (1999) The expression of several mitochondrial and nuclear genes encoding the subunits of electron transport chain enzyme complexes, cytochrome c oxidase, and NADH dehydrogenase, in different brain regions in Alzheimer's disease. Neurochem. Res. 24, 767-774.
3. Aksenov M. Y., Aksenova M. V., Butterfield D. A. and Markesbery W. R. (2000) Oxidative modification of creatine kinase BB in Alzheimer's disease brain. J. Neurochem. 74, 2520-2527.
4. Aksenov M. Y., Aksenova M. V., Butterfield D. A., Geddes J. W. and Markesbery W. R. (2001) Protein oxidation in the brain in Alzheimer's disease. Neuroscience 103, 373-383.
5. Austen B. M., Frears E. R. and Davies H. (2000) The use of Seldi ProteinChip™ arrays to monitor production of Alzheimer's β-amyloid in transfected cells. J. Peptide Sci. 6, 459-469.
6. Bajo M., Yoo B. C., Cairns N., Gratzer M. and Lubec G. (2001) Neurofilament protein NF-L, NF-M, NF-H in brain of patients with Down syndrome and Alzheimer's disease. Amino Acids 21, 293-301.
7. Balcz B., Kirchner L., Cairns N., Fountoulakis M. and Lubec G. (2001) Increased brain protein levels of carbonyl reductase and alcohol dehydrogenase in Down syndrome and Alzheimer's disease. J. Neural. Transm. Suppl. 61, 193-201.
8. Brining S. K., Chen N., Yi D. and Chrambach A. (1999) Gel electrophoretic distinction between toxic and nontoxic forms of beta-amyloid (140). Electrophoresis 20, 1398-1402.
9. Bush A. I. (2003) The metallobiology of Alzheimer's Disease. Trends Neurosci. 26, 207-214.
10. Butterfield D. A. (2002) Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. Free Rad. Res. 36, 1307-1313.
11. Butterfield D. A. and Lauderback C. M. (2002) Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic. Biol. Med. 32, 1050-1060.
12. Butterfield D. A. and Stadtman E. R. (1997) Protein oxidation processes in aging brain. Adv. Cell Aging Gerontol. 2, 161-191.
13. Butterfield D. A., Drake J., Pocernich C. and Castegna A. (2001) Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol. Med. 7, 548-554.
14. Butterfield D. A., Castegna A., Lauderback C. M. and Drake J. (2002) Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol. Aging 23, 655-664.
15. Cai H., Wang Y., McCarthy D., Wen H., Borchet D. R., Price D. L. and Wong P. C. (2001) BACE1 is the major β-secretase for generation of Aβ peptides by neurons. Nat. Neurosci. 4, 233-234.
16. Castegna A., Aksenov M., Aksenova M., Thongboonkerd V., Klein J. B., Pierce W. M., Booze R., Markesbery W. R. and Butterfield D. A. (2002a) Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain: part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Rad. Biol. Med. 33, 562-571.
17. Castegna A., Aksenov M., Thongboonkerd V., Klein J. B., Pierce W. M., Booze R., Markesbery W. R. and Butterfield D. A. (2002b) Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain: part II: dihydropyrimidinase related protein II, α-enolase and heat shock cognate 71. J. Neurochem. 82, 1524-1532.
18. Castegna A., Thongboonkerd V., Klein J. B., Lynn B., Markesbery W. R. and Butterfield D. A. (2003) Proteomic identification of nitrated proteins in Alzheimer's disease brain. J. Neurochem. 85, 1394-1401.
19. Chen F., Yang D. S., Petanceska S., Yang A., Tandon A. YuG., Rozmahel R., Ghiso J., Nishimura M., Zhang D. M., Kawarai T., Levesque G., Mills J., Levesque L., Song Y. Q., Rogaeva E., Westaway D., Mount H., Gandy S., St George-Hyslop P. and Fraser P. E. (2000) Carboxyl-terminal fragments of Alzheimer's β-amyloid precursor protein accumulate in restricted and unpredicted intracellular compartments in presenilin 1-deficient cells. J. Biol. Chem. 275, 36794-36802.
20. Cheon M. S., Fountoulakis M., Caims N., Dierssen M., Herkner K. and Lubec G. (2001) Decreased protein levels of stathmin in adult brains with Down syndrome and Alzheimer's disease. J. Neural Transm. Suppl. 61, 281-288.
21. Choi J., Malakowsky C. A., Talent J. M., Conrad C. C. and Gracy R. W. (2002) Identification of oxidized plasma proteins in Alzheimer's disease. Biochem. Biophys. Res. Commun. 293, 1566-1570.
22. Coleman P. D. and Flood D. G. (1987) Neuron numbers and dendritic extent in normal aging and Alzheimer's disease. Neurobiol. Aging 8, 521-545.
23. Daleke D. L. and Lyles J. V. (2000) Identification and purification of aminophospholipid flippases. Biochim. Biophys. Acta 1486, 108-127.
24. Davidsson P., Westman-Brinkmalm A., Nilsson C. L., Lindbjer M., Paulson L., Andreasen N., Sjögren M. and Blennow K. (2002) Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. Clin. Neurosci. Neuropathol. 13, 611-615.
25. Davies P. (1999) Challenging the cholinergic hypothesis in Alzheimer disease. JAMA 281, 1433-1434.
26. Engidawork E., Gulesserian T., Balic N., Caims N. and Lubec G. (2001a) Changes in nicotinic acetylcholine receptor subunits expression in brain of patients with Down syndrome and Alzheimer's disease. J. Neural Transm. Suppl. 61, 211-222.
27. Engidawork E., Gulesserian T., Yoo B. C., Cairns N. and Lubec G. (2001b) Alteration of caspases and apoptosis-related proteins in brains of patients with Alzheimer's disease. Biochem. Biophys. Res. Commun. 281, 84-93.
28. Engidawork E., Gulesserian T., Seidl R., Cairns N. and Lubec G. (2001c) Expression of apoptosis related proteins in brains of patients with Alzheimer's disease. Neurosci. Lett. 303, 79-82.
29. Gibb G. M., Pearce J., Betts J. C., Lovestone S., Hoffmann M. M., Maerz W., Blackstock W. P. and Anderton B. H. (2000) Differential effects of apolipoprotein E isoforms on phosphorylation at specific sites on tau by glycogen synthase kinase-3 beta identified by nano-electrospray mass spectrometry. FEBS Lett. 485, 99-103.
30. Greber S., Lubec G., Caims N. and Fountoulakis M. (1999) Decreased levels of synaptosomal associated protein 25 in the brain of patients with Down syndrome and Alzheimer's disease. Electrophoresis 20, 928-934.
31. Hanger D. P., Betts J. C., Loviny T. L., Blackstock W. P. and Anderton B. H. (1998) New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J. Neurochem. 71, 2465-2476.
32. Hensley K., Hall N., Subramaniam R., Cole P., Harris M., Aksenov M., Aksenova M., Gabbita P., Wu J. F., Carney J. M., Lovell M., Markesbery W. R. and Butterfield D. A. (1995) Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J. Neurochem. 65, 2146-2156.
33. Hesse C., Nilsson C. L., Blennow K. and Davidsson P. (2001) Identification of the apolipoprotein E4 isoform in cerebrospinal fluid with preparative two-dimensional electrophoresis and matrix assisted laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 22, 1834-1837.
34. Hoogland C., Sanchez J. C., Tonella L., Binz P. A., Bairoch A., Hochstrasser D. F. and Appel R. D. (2000) The 1999 SWISS-2DPAGE database update. Nucleic Acids Res. 28, 286-288.
35. Issaq H. J., Veenstra T. D., Conrads T. P. and Felschow D. (2002) The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem. Biophys. Res. Commun. 292, 587-592.
36. Kaji H., Tsuji T., Mawuenyega K. G., Wakamiya A., Taoka M. and Isobe T. (2000) Profiling of Caenorhabditis elegans proteins using twodimensional gel electrophoresis and matrix assisted laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 21, 1755-1765.
37. Keller J., Hanni K. B. and Markesberry W. M. (2000) Impaired proteasome function in Alzheimer's disease. J. Neurochem. 75, 436-439.
38. Kim S. H. and Lubec G. (2001) Brain α-endosulfine is manifold decreased in brains from patients with Alzheimer's disease: a tentative marker and drug target? Neurosci. Lett. 310, 77-80.
39. Kim S. H., Caims N., Fountoulakis M. and Lubec G. (2001a) Decreased brain histamine-releasing factor protein in patients with Down syndrome and Alzheimer's disease. Neurosci. Lett. 300, 41-44.
40. Kim S. H., Fountoulakis M., Cairns N. and Lubec G. (2001b) Protein levels of human peroxiredoxin subtypes in brains of Alzheimer's disease and Down syndrome. J. Neural Transm. Suppl. 61, 223-235.
41. Kim S. H., Naim A. C., Caims N. and Lubec G. (2001c) Decreased levels of ARPP-19 and PKA in brains of Down syndrome and Alzheimer's disease. J. Neural Transm. Suppl. 61, 263-272.
42. Kim S. H., Vlkolinský R., Caims N., Fountoulakis M. and Lubec G. (2001d) The reduction of NADH Ubiquinone oxidoreductase 24-and 75-kDa subunits in brains of patients with Down syndrome and Alzheimer's disease. Life Sci. 68, 2741-2750.
43. Kim S. H., Fountoulakis M., Caims N. J. and Lubec G. (2002) Human brain nucleoside diphosphate kinase activity is decreased in Alzheimer's disease and Down syndrome. Biochem. Biophys. Res. Commun. 296, 970-975.
44. Korolainen M. A., Goldsteins G., Alafuzoff I., Koistinaho J. and Pirttila T. (2002) Proteomic analysis of protein oxidation in Alzheimer's disease brain. Electrophoresis 23, 3428-3433.
45. Krapfenbauer K., Engidawork E., Cairns N., Fountoulkis M. and Lubec G. (2003) Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders. Brain Res. 967, 152-160.
46. Lauderback C. M., Hackett J. M., Huang F. F., Keller J. N., Szweda L. I., Markesbery W. R. and Butterfield D. A. (2001) The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Aβ1-42. J. Neurochem. 78, 413-416.
47. Lauderback C. M., Kanski J., Hackett J. M., Maeda N., Kindy M. S. and Butterfield D. A. (2002) Apolipoprotein E modulates Alzheimer's Aβ (1-42)-induced oxidative damage to synaptosomes in an allele-specific manner. Brain Res. 924, 90-97.
48. Lovell M. A., Robertson J. D., Teesdale W. J., Campbell J. L. and Markesbery W. R. (1998) Copper, iron and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci. 158, 47-52.
49. Lovell M. A., Xie C. and Markesbery W. R. (2001) Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol. Aging 22, 187-194.
50. Lubec G., Nonaka M., Krapfenbauer K., Gratzer M., Cairns N. and Fountoulakis M. (1999) Expression of the dihydropyrimidinase related protein 2 (DRP-2) in Down syndrome and Alzheimer's disease brain is downregulated at the mRNA and dysregulated at the protein level. J. Neural Transm. Suppl. 57, 161-177.
51. Lund E. T., McKenna R., Evans D. B., Sharma S. K. and Mathews W. R. (2001) Characterization of the in vitro phosphorylation of human tau by tau protein kinase II (cdk5/p20) using mass spectrometry. J. Neurochem. 76, 1221-1232.
52. Mark R. J., Pang Z., Geddes J. W., Uchida K. and Mattson M. P. (1997) Amyloid β-peptide impairs glucose transport in hippocampal and cortical neurons: involvment of membrane lipid peroxidation. J. Neurosci. 17, 1046-1054.
53. Markesbery W. R. (1997) Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 23, 134-147.
54. Markesbery W. R. and Lovell M. A. (1998) Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol. Aging 19, 33-36.
55. Masliah E., Alford M., DeTeresa R., Mallory M. and Hansen L. (1995) Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. Ann. Neurol. 40, 759-766.
56. Mattson M. P., Gary D. S., Chan S. L. and Duan W. (2001) Perturbed endoplasmic reticulum function, synaptic apoptosis and the pathogenesis of Alzheimer's disease. Biochem. Soc. Symp. 67, 151-162.
57. Merchant M. and Weinberger S. R. (2000) Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 21, 1164-1167.
58. Molloy M. P. (2000) Two-dimensional electrophoresis of membrane proteins using immobilized pH gradients. Anal. Biochem. 280, 1-10.
59. Morishima Y., Gotoh Y., Zieg J., Barrett T., Takano H., Flavell R., Davis R. J., Shirasaki Y. and Greenberg M. E. (2001) Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J. Neurosci. 21, 7551-7560.
60. Nagele R. G., D'Andrea M. R., Anderson W. J. and Wang H. Y. (2002) Intracellular accumulation of β-amyloid (1-42) in neurons is facilitated by the α7 nicotinic acetylcholine receptor in Alzheimer's disease. Neuroscience 110, 199-211.
61. Prange A., Schaumlöffel D., Brätter P., Richarx A. and Wolf C. (2001) Species analysis of metallothionein isoforms in human brain cytosols by use of capillary electrophoresis hyphenated to inductively coupled plasma-sector field mass spectrometry. J. Anal. Chem. 371, 764-774.
62. Rabilloud T. (2002) Two-dimensional gel electrophoresis in proteomics: old, old fashioned, but it still climbs up the mountains. Proteomics 2, 3-10.
63. Santoni V., Molloy M. and Rabilloud T. (2000) Membrane proteins and proteomics: un amour impossible? Electrophoresis 21, 1054-1070.
64. Schonberger S. J., Edgar P. F., Kydd R., Faull R. L. M. and Cooper G. J. S. (2001) Proteomic analysis of the brain in Alzheimer's disease: molecular phenotype of a complex disease process. Proteomics 1, 1519-1528.
65. Schuller E., Gulesserian T., Seidl R., Cairns N. and Lubec G. (2001) Brain t-complex polypeptide 1 (TCP-1) related to its natural substrate β1 tubulin is decreased in Alzheimer's disease. Life Sci. 69, 263-270.
66. Selkoe D. J. (2001a) Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J. Alzheimer's Dis. 3, 75-80.
67. Selkoe D. J. (2001b) Presenilin, notch, and the genesis and treatment of Alzheimer's disease. Proc. Natl Acad. Sci. USA 98, 11039-11041.
68. Shim K. S. and Lubec G. (2002) Drebrin, a dendritic spine protein, is manifold decreased in brains of patients with Alzheimer's disease and Down syndrome. Neurosci. Lett. 324, 209-212.
69. Shringarpure R., Grune T. and Davies K. J. (2001) Protein oxidation and 20S proteasome-dependent proteolysis in mammalian cells. Cell. Mol. Life Sci. 58, 1442-1450.
70. Skehel J. M., Schneider K., Murphy N., Graham A., Benson G. M., Cutler P. and Camilleri P. (2000) Phenotyping apolipoprotein E*3-leiden transgenic mice by two-dimensional polyacrylamide gel electrophoresis and mass spectrometric identification. Electrophoresis 21, 2540-2545.
71. Smith C. D., Carney J. M., Starke-Reed P. E., Oliver C. N., Stadtman E. R., Floyd R. A. and Markesbery W. R. (1991) Protein oxidation in aging brain. Proc. Natl Acad. Sci. USA 88, 10540-10543.
72. Smith M. A., Richey Harris P. L., Sayre L. M., Beckman J. S. and Perry G. (1997) Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci. 17, 2653-2657.
73. Smolka M. B., Zhou H., Purkayastha S. and Aebersold R. (2001) Optimization of the isotope-coded affinity tag-labeling procedure for quantitative proteome analysis. Anal Biochem. 297, 25-31.
74. Strittmatter W. J., Saunders A. M., Goedert M., Weisgraber K. H., Dong L. M., Jakes R., Huang D. Y., Pericak-Vance M., Schmechel D. and Roses A. D. (1994) Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc. Natl Acad. Sci. USA 91, 11183-11186.
75. Subramaniam R., Roediger F., Jordan B., Mattson M. P., Keller J. N., Waeg G. and Butterfield D. A. (1997) The lipid peroxidation product, 4-hydroxy-2-trans-nonenal, alters the conformation of cortical synaptosomal membrane proteins. J. Neurochem. 69, 1161-1169.
76. Tilleman K., Van den Haute C., Geerts H., van Leuven F., Esmans E. L. and Moens L. (2002a) Proteomics analysis of the neurodegeneration in the brain of tau transgenic mice. Proteomics. 2, 656-665.
77. Tilleman K., Stevens I., Spittaels K., Haute C. V., Clerens S., Van Den Bergh G., Geerts H., Van Leuven F., Vandesande F. and Moens L. (2002b) Differential expression of brain proteins in glycogen synthase kinase-3 transgenic mice: a proteomics point of view. Proteomics 2, 94-104.
78. Tozaki H., Matsumoto A., Kanno T., Nagai K., Nagata T., Yamamoto S. and Nishizaki T. (2002) The inhibitory and facilitatory actions of amyloid-beta peptides on nicotinic ACh receptors and AMPA receptors. Biochem. Biophys. Res. Commun. 294, 42-45.
79. Tsugita A., Kawakami T., Uchida T., Sakai T., Kamo M., Matsui T., Watanabe Y., Morimasa T., Hosokawa K. and Toda T. (2000) Proteome analysis of mouse brain: two-dimensional electrophoresis profiles of tissue proteins during the course of aging. Electrophoresis 21, 1853-1871.
80. Tsuji T., Shimohama S., Kamiya S., Sazuka T. and Ohara O. (1999) Analysis of brain proteins in Alzheimer's disease using high-resolution two-dimensional gel electrophoresis. J. Neurol. Sci. 166, 100-106.
81. Ueno I., Sakai T., Yamaoka M., Yoshida R. and Tsugita A. (2000) Analysis of blood plasma proteins in patients with Alzheimer's disease by two-dimensional electrophoresis, sequence homology and immunodetection. Electrophoresis 21, 1832-1845.
82. Varadarajan S., Yatin S., Aksenova M. and Butterfield D. A. (2000) Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J. Struct. Biol. 130, 184-208.
83. Vijayan S., El-Akkad E., Grundke-Iqbal I. and Iqbal K. (2001) A pool of beta-tubulin is hyperphosphorylated at serine residues in Alzheimer disease brain. FEBS Lett. 509, 375-381.
84. Vlkolinsk, R., Cairns N., Fauntoulakis M. and Lubec G. (2001) Decreased brain levels of 2′,3-cyclic nucleotide-3′-phosphodiesterase in Down syndrome and Alzheimer's disease. Neurobiol. Aging 22, 547-553.
85. Wandosell F., Serrano L., Hernandez M. A. and Avila J. (1986) Phosphorylation of tubulin by a calmodulin-dependent protein kinase. J. Biol. Chem. 261, 10332-10339.
86. Yatin S. M., Varadarajan S. and Butterfield D. A. (2000) Vitamin E prevents Alzheimer's amyloid beta-peptide (1-42)-induced neuronal protein oxidation and reactive oxygen species production. J. Alzheimer. Dis. 2, 123-131.
87. Yatin S. M., Yatin M., Aulick T., Ain K. B. and Butterfield D. A. (1999) Alzheimer's amyloid beta-peptide associated free radicals increase rat embryonic neuronal polyamine uptake and omithine decarboxylase activity: protective effect of vitamin E. Neurosci. Lett. 263, 17-20.
88. Yoo B. C., Fountoulakis M., Cairns N. and Lubec G. (2001a) Changes of voltage-dependent anion-selective channel proteins VDAC1 and VDAC2 brain levels in patients with Alzheimer's disease and Down syndrome. Electrophoresis 22, 172-179.
89. Yoo B. C., Kim S. H., Cairns N., Fountoulakis M. and Lubec G. (2001b) Deranged expression of molecular chaperones in brains of patients with Alzheimer's disease. Biochem. Biophys. Res. Commun. 280, 249-258.